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OBJECTIVES: Drug-Related Problems (DRPs) occur frequently with antidepressants
leading to treatment failure and increasedmorbidity in the depressed patient. The
study was designed to collect preliminary data related to antidepressant drug re-
lated problems and treatment failure in India.METHODS: A cross sectional obser-
vational study was carried out for a period of four months at a mental health
facility in Udupi, India. All the prescriptions of the study population were screened
for Drug Related Problems (DRPs) such as ADRs and DDIs by using a computerized
database system. These data were assessed for the pattern of the ADRs with re-
spect to patient demographics, nature of the reaction, outcome of the reactions,
causality, severity and preventability. RESULTS: A total of 120 patients were en-
rolled in the study and 33 of them developed 50 Drug Related Problems (DRPs), in
those 24 Drug-Drug Interactions (DDIs) and 26 Adverse Drug Reactions (ADRs). The
overall incidence of DRPs in the present study was 27.5%. Among the 33 patients
and the significant proportions of DRPs were in female with [p 0.01] than inmale.
Most of the patients who had developed DRPs was in the age group of 36-55 yrs
[p0.01] followed by other age. The common ADRs observed were hyponatremia
and headache. Considering outcomes, 20 (76.9%) of cases recovered fromADRs and
while assessing the preventability, 20 (76.9%) of the ADRs were definitely prevent-
able. When causality assessments were conducted, we found that that majority of
ADRs were probable and were found to be mild to moderately severe.
CONCLUSIONS:An ongoing drugmonitoring program aimed at assessing common
drug-related problemsmay be key in improving treatment effectiveness in patients
with depression. The involvement of community pharmacists in a pilot psychiatric
drugmonitoring program in India assisted in the identification of common adverse
drug related problems in these patients.
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A large number of depressed patients remained unremitting despite existing
classes of antidepressants (SSRI,SNRI andNaSSa). ShouldAgomelatine, a new class
of antidepressant reflect different clinical value in daily practice? OBJECTIVES: To
evaluate clinical value and safety of Agomelatine on basis of daily practice inman-
agement of depressive disorders.METHODS: Newly diagnosed depressed and un-
remitting depressed patients diagnosed by psychiatrists (per DSM-IV criteria) were
prescribed Agomelatine 25 mg daily, followed-up at week 2, 6, 12 respectively. At
follow-up, efficacy of Agomelatine were assessed with the 10-items standardized
Thai version MA¨DRS, Clinical Global Improvement score (both CGI-S, CGI-I) by
psychiatrists. Acceptability and safety were assessed through direct patients’
interviews. RESULTS: 133 depressed patients, mean duration of illness of 4.3 years,
mean number of episodes of 2.4. Anxiety disorder and Insomnia were diagnosed in
12.8% and 8.3% of patients respectively. 63% and 37% of patients were treated with
Agomelatine as monotherapy and combination with other psychotropic agents.
The efficacy assessment as reflected by mean MA¨DRS score reduction based on
MA¨DRS severity level. The mean(SD) MA¨DRS score for all patients (N133), pa-
tients with MA¨DRS  20(N67), MA¨DRS between 20-24(N32) and MA¨DRS 
25(N34) at baseline of 21.40(5.25),16.91(1.75), 23.6(1.38) and 28.7(1.93) were signif-
icantly reduced with mean score reduction (95% CI)at p0.001 by 10.2(9.3-11.1),
6.3(5.8-6.8), 11.2(10.0-12.5) and  16.9(15.5-18.2) at the end of 12-weeks respec-
tively. The clinical global improvement of depression after 12 week measured by
mean (SD) of CGI-S and CGI-I significantly improved for all patients at 1.65(0.79)
and 3.7(1.02) respectively with therapeutic index of 2.52 (1.11). The reported
adverse effects were mild and transient, mainly dizziness and headache. No sus-
pect case of abnormal liver enzyme was noted. CONCLUSIONS: Agomelatine is a
clinically effective, well-tolerated antidepressant in Thai depressed patients what-
ever the severity of depression. Agomelatine is endowed with moderate to high
therapeutic value for management of depressive disorders in Thailand.
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OBJECTIVES: Dementia is a progressive disease characterized by behavioral, func-
tional, and cognitive deficits that affects patients and their families on multiple
levels. The aim of this study was to estimate the impact of dementia care on
caregivers at personal, emotional, social, professional, and financial levels in
China.METHODS:Amulticenter, cross-sectional hospital based study in dementia
patients was conducted between September 2009 and December 2009 in 48 Tier 3
hospitals across seven regions ofmainland China. Patients with suspected demen-
tia and their caregivers were given the option to participate and complete an In-
formedConsent Form. Consented patients underwent standard dementia and sub-
type diagnosis using criteria from Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV). Level of caregiver burden was measured using the Chinese
validated Zarit Burden Interview (ZBI), which was designed to reflect the stresses
experienced by caregivers of dementia patients. Costs were converted into US
dollars (6.83 Yuan 1 USD). RESULTS: A total of 1425 caregivers participated in the
caregiver assessment interview. Results showed that dementia care had the great-
est impact on the professional lives of caregivers, with 25.3% of all respondents
reporting a reduction to their work schedule in the past month and a greater re-
duction in work hours compared with counterparts who cared for patients with
newly diagnosed dementia. With regard to personal, social, and emotional well-
being, most caregivers reported that dementia care had little to no impact. Costs
associated with dementia care ranged $55–$214 (USD) and total cost averaged $575
(USD) per month. This amount exceeds the reported per capita disposable income
of urban dwellers ($210). CONCLUSIONS: The results reported here are the first to
describe the burden of dementia care among a cohort of caregivers in China, and
provides some insight into the obstacles facing the country with the fastest grow-
ing elderly population in the world.
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OBJECTIVES: In Taiwan, the ratio of aging population is gradually increasing and
nowadays the old age depression becomes amajor issue of themental disorder and
integration disease prevention program. Also, the old age people always suffered
from multiple chronic diseases; thus, the association of the diseases and medica-
tions could be studied in order to develop the geriatric pharmaceutical care model.
METHODS: The claims database of 2000 to 2011 from the Kaohsiung Veterans
General Hospital was used to select all the cases from the old age people (65yrs.).
By using the anatomical therapeutic and chemical classification system, we sort
out all the depression cases of the ATC code N06A for further evaluation. All the
statistical work was completed using SPSS 19.0 Base for windows. RESULTS: There
were 92,975 cases matched the acceptance criteria and a total of 10,310 patients
identified inwhich 6836weremale and 3474were female. Themedian age formale
was 79 years old whereas 76 years old for female. During the 12-year study period,
the median length of drug day for male was 56 days ranged from 2 to 5,276 longer
than 44 ranged from 3 to 4,868 days for female. There was statistical significance
difference (p0.01) for gender usingMann-Whitney Test. CONCLUSIONS:Owing to
the change from off pattern drugs to generic drugs like the selective serotonin re-
uptake inhibitor, Prozac, the drug fee has made a remarkable decrease during these
years. Instead, the tetra-cyclic antidepressant i.e. mirtazapine and the serotonin-nor-
epinephrine reuptake inhibitors i.e. milnacipran have increased significantly.
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OBJECTIVES: This study examined whether participation in a weight control pro-
gramwas also associated with improvements in clinical and functional outcomes.
METHODS: A post hoc analysis was conducted using data from the Chinese sub-
group (n330) of amulticountry, 6-month, prospective, observational study of out-
patients with schizophrenia who were initiated or switched to oral olanzapine. At
study entry, and each month for 6 months, participants were assessed with the
Clinical Global Impression of Severity (CGI-S), and measures of patient insight and
functional status. Change in level of illness severity, response rate, and time to
response (all per CGI-S), impaired work activities and insight level were compared
between two groups: 1) 153 patients who participated in a weight control program
at study entry or during the study (WCP), and; 2) 177 patients who did not partici-
pate in theweight control programat any timeduring the study (NWCP). Univariate
comparisons were conducted using Fisher’s exact tests for categorical variables
and ANOVA for continuous variables. Kaplan-Meier survival analysis was used to
assess time to response. RESULTS: Participants had amean age 29.0 years and 29.3
years, and 51.0% and 57.6% were female for WCP and NWCP, respectively. Average
initiated daily dose for olanzapine was 9.5  5.4mg. Weight control program par-
ticipants gained less weight than non-participants (LSmeans weight change: 3.9kg
vs. 4.9kg, p0.03) and showed statistically significant better clinical and functional
outcomes: greater improvement in illness severity (2.93 vs2.06 p0.001), higher
treatment response rates (94.1% vs 80.9% p0.001), shorter time to response
(p0.001), higher proportion of patients without impaired work activities
(p0.001), and greater improvement in patients’ insight (p0.001). CONCLUSIONS:
Participation in a weight control program may not only lower the risk of clinically
significant weight gain in olanzapine-treated patients, but may also be associated
with additional clinical and functional benefits.
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FACTORS ASSOCIATED WITH MEDICAL EXPENDITURE FOR DEMENTIA IN
SOUTH KOREA
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